Eli Lilly and Co (LLY) Shares Bought by First Trust Advisors LP

First Trust Advisors LP increased its position in shares of Eli Lilly and Co (NYSE:LLY) by 25.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 477,290 shares of the company’s stock after purchasing an additional 95,584 shares during the quarter. First Trust Advisors LP’s holdings in Eli Lilly and were worth $40,312,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Greenleaf Trust lifted its stake in Eli Lilly and by 17.9% during the fourth quarter. Greenleaf Trust now owns 7,248 shares of the company’s stock worth $612,000 after purchasing an additional 1,102 shares during the last quarter. Public Employees Retirement System of Ohio lifted its stake in Eli Lilly and by 0.5% during the fourth quarter. Public Employees Retirement System of Ohio now owns 688,212 shares of the company’s stock worth $58,126,000 after purchasing an additional 3,679 shares during the last quarter. Pinnacle Financial Partners Inc. lifted its stake in Eli Lilly and by 12.8% during the fourth quarter. Pinnacle Financial Partners Inc. now owns 41,844 shares of the company’s stock worth $3,534,000 after purchasing an additional 4,761 shares during the last quarter. Cetera Investment Advisers lifted its stake in Eli Lilly and by 7.8% during the fourth quarter. Cetera Investment Advisers now owns 11,243 shares of the company’s stock worth $944,000 after purchasing an additional 818 shares during the last quarter. Finally, Barings LLC lifted its stake in Eli Lilly and by 87.8% during the fourth quarter. Barings LLC now owns 86,073 shares of the company’s stock worth $7,269,000 after purchasing an additional 40,252 shares during the last quarter. Hedge funds and other institutional investors own 75.71% of the company’s stock.

Several equities analysts recently issued reports on the company. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, December 5th. Credit Suisse Group restated a “hold” rating and set a $80.00 price objective on shares of Eli Lilly and in a research note on Friday, February 2nd. Leerink Swann raised their target price on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and raised their target price for the company from $85.52 to $115.00 in a research note on Friday, January 5th. Finally, Goldman Sachs Group cut Eli Lilly and from a “buy” rating to a “neutral” rating and raised their target price for the company from $86.98 to $95.00 in a research note on Tuesday, January 16th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $92.02.

Eli Lilly and Co (NYSE:LLY) opened at $78.97 on Monday. The company has a market capitalization of $86,953.48, a price-to-earnings ratio of 18.45, a PEG ratio of 1.47 and a beta of 0.23. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Co has a fifty-two week low of $73.69 and a fifty-two week high of $89.09.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. The company had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the company earned $0.95 earnings per share. sell-side analysts predict that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.85%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is -1,124.94%.

In other news, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.09, for a total value of $72,981.00. Following the transaction, the insider now directly owns 4,130 shares in the company, valued at $334,901.70. The disclosure for this sale can be found here. Insiders have sold 259,610 shares of company stock worth $22,727,406 over the last three months. Corporate insiders own 0.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Eli Lilly and Co (LLY) Shares Bought by First Trust Advisors LP” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/02/19/eli-lilly-and-co-lly-shares-bought-by-first-trust-advisors-lp.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Eli Lilly and Co (LLY) Shares Bought by First Trust Advisors LP

First Trust Advisors LP increased its position in shares of Eli Lilly and Co (NYSE:LLY) by 25.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 477,290 shares of the company’s stock after acquiring an additional 95,584 shares during the period. First Trust Advisors LP’s holdings in Eli Lilly and were worth $40,312,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Airain ltd acquired a new position in shares of Eli Lilly and in the 2nd quarter valued at $567,000. Buckingham Asset Management LLC boosted its position in shares of Eli Lilly and by 21.3% in the 2nd quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock valued at $266,000 after purchasing an additional 568 shares during the period. BSW Wealth Partners boosted its position in shares of Eli Lilly and by 0.6% in the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock valued at $393,000 after purchasing an additional 27 shares during the period. Mirador Capital Partners LP boosted its position in Eli Lilly and by 5.3% during the 2nd quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock worth $1,011,000 after acquiring an additional 619 shares during the period. Finally, Candriam Luxembourg S.C.A. boosted its position in Eli Lilly and by 166.7% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 430,424 shares of the company’s stock worth $36,818,000 after acquiring an additional 269,038 shares during the period. 75.71% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Eli Lilly and Co (NYSE:LLY) opened at $78.97 on Monday. The stock has a market capitalization of $86,953.48, a PE ratio of 18.45, a PEG ratio of 1.47 and a beta of 0.23. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Co has a 1-year low of $73.69 and a 1-year high of $89.09.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. The business had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The firm’s revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.95 EPS. sell-side analysts anticipate that Eli Lilly and Co will post 4.87 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 2.85%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s payout ratio is currently -1,124.94%.

In related news, SVP Jeffrey N. Simmons sold 12,500 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $86.46, for a total value of $1,080,750.00. Following the transaction, the senior vice president now directly owns 124,522 shares of the company’s stock, valued at approximately $10,766,172.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.09, for a total value of $72,981.00. Following the completion of the transaction, the insider now directly owns 4,130 shares in the company, valued at $334,901.70. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 259,610 shares of company stock valued at $22,727,406. 0.20% of the stock is owned by corporate insiders.

A number of equities research analysts have commented on LLY shares. Berenberg Bank restated a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research report on Thursday, October 26th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a research report on Thursday, October 26th. Jefferies Group set a $100.00 price objective on Eli Lilly and and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and raised their price objective for the stock from $85.52 to $115.00 in a research report on Friday, January 5th. Finally, Morgan Stanley raised their price objective on Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 21st. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $92.02.

COPYRIGHT VIOLATION NOTICE: “Eli Lilly and Co (LLY) Shares Bought by First Trust Advisors LP” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/02/19/eli-lilly-and-co-lly-shares-bought-by-first-trust-advisors-lp.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply